Hereditary Diffuse Gastric Cancer With Poorly Differentiated Gallbladder Adenocarcinoma: A Case Report Suggesting Carcinogenesis in the Stomach and Gallbladder Caused by a Pathogenic Germline Variant in CDH1 .

In VivoJan 1, 2026

Masato Hayashi, Naoto Kubota, Makoto Abe et al.

✦ AI-curated · Sources linked

Case in brief

A 67-year-old woman was referred for management of gallbladder cancer after cholecystectomy for progressive gallbladder wall thickening. Pathology showed poorly differentiated adenocarcinoma invading the subserosa, with reduced E-cadherin expression. Her father and brother had died of gastric cancer at young ages, prompting gastric endoscopy; biopsies of multiple faded mucosal lesions showed signet-ring cell carcinoma. Gastrectomy and gallbladder bed resection revealed 22 gastric malignancies, predominantly pT1a signet-ring cell carcinomas, with variable or absent E-cadherin expression. Germline testing identified a pathogenic CDH1 frameshift variant.

What made this case unusual

The case combined hereditary diffuse gastric cancer with a primary, poorly differentiated gallbladder adenocarcinoma, both in the setting of a pathogenic germline CDH1 variant. The authors suggest a possible contribution of the variant to gallbladder carcinogenesis.

Diagnostic / clinical pearl

Poorly differentiated gallbladder adenocarcinoma with reduced E-cadherin expression, particularly alongside a strong family history of gastric cancer, may warrant evaluation for hereditary diffuse gastric cancer.

Source

Published in In Vivo. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.